What is the best surveillance for hepatocellular carcinoma in chronic carriers of hepatitis B?

Journal of Family Practice

Volumn 55, Issue 2, 2006, Pages 155-156

  Rugge, J Bruin ^a   Lochner, Jennifer ^a   Judkins, Dolores ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; HEPATITIS B SURFACE ANTIGEN;

CANCER STAGING; CLINICAL TRIAL; EARLY CANCER; ENDEMIC DISEASE; EVIDENCE BASED MEDICINE; HEALTH SURVEY; HEPATITIS B; HIGH RISK POPULATION; HUMAN; LIVER CELL CARCINOMA; MASS SCREENING; MORTALITY; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; ULTRASOUND; VIRUS CARRIER;

CARCINOMA, HEPATOCELLULAR; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MASS SCREENING; RISK FACTORS;

EID: 32844463930     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (6)

1. Sherman M. Screening for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005; 19:101-118.
2. Wun YT, Dickinson JA. Alpha-fetoprotein and/or ultrasonography for liver cancer screening in patients with chronic hepatitis B. Cochrane Database Syst Rev 2003; (2):CD002799.
3. Yang B, Zhang B, Xu Y, et al. Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol 1997; 123:357-360.
4. Zhang B, Yang B, Tang Z. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130:417-422.
5. Sherman M, Peltekian K, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a north American urban population. Hepatology 1995; 22:432-438.
6. Lok A, McMahon B. AASLD practice guidelines: chronic Hepatitis B. American Association for the Study of Liver Disease web site. Available at: https://www.aasld.org/eweb/docs/chronichep_B.pdf. Accessed on January 9, 2006.